Top

Published in:

Open Access 01-09-2020 | Cancer Therapy

CDK7 inhibitors as anticancer drugs

Authors: Georgina P. Sava, Hailing Fan, R. Charles Coombes, Lakjaya Buluwela, Simak Ali

Published in: Cancer and Metastasis Reviews | Issue 3/2020

Abstract

Cyclin-dependent kinase 7 (CDK7), along with cyclin H and MAT1, forms the CDK-activating complex (CAK), which directs progression through the cell cycle via T-loop phosphorylation of cell cycle CDKs. CAK is also a component of the general transcription factor, TFIIH. CDK7-mediated phosphorylation of RNA polymerase II (Pol II) at active gene promoters permits transcription. Cell cycle dysregulation is an established hallmark of cancer, and aberrant control of transcriptional processes, through diverse mechanisms, is also common in many cancers. Furthermore, CDK7 levels are elevated in a number of cancer types and are associated with clinical outcomes, suggestive of greater dependence on CDK7 activity, compared with normal tissues. These findings identify CDK7 as a cancer therapeutic target, and several recent publications report selective CDK7 inhibitors (CDK7i) with activity against diverse cancer types. Preclinical studies have shown that CDK7i cause cell cycle arrest, apoptosis and repression of transcription, particularly of super-enhancer-associated genes in cancer, and have demonstrated their potential for overcoming resistance to cancer treatments. Moreover, combinations of CDK7i with other targeted cancer therapies, including BET inhibitors, BCL2 inhibitors and hormone therapies, have shown efficacy in model systems. Four CDK7i, ICEC0942 (CT7001), SY-1365, SY-5609 and LY3405105, have now progressed to Phase I/II clinical trials. Here we describe the work that has led to the development of selective CDK7i, the current status of the most advanced clinical candidates, and discuss their potential importance as cancer therapeutics, both as monotherapies and in combination settings. ClinicalTrials.gov Identifiers: NCT03363893; NCT03134638; NCT04247126; NCT03770494.

Schachter, M. M., & Fisher, R. P. (2013). The CDK-activating kinase Cdk7. Cell Cycle, 12(20), 3239–3240. https://doi.org/10.4161/cc.26355.CrossRefPubMedPubMedCentral

Larochelle, S., Merrick, K. A., Terret, M.-E., Wohlbold, L., Barboza, N. M., Zhang, C., Shokat, K. M., Jallepalli, P. V., & Fisher, R. P. (2007). Requirements for Cdk7 in the assembly of Cdk1/Cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Molecular Cell, 25(6), 839–850. https://doi.org/10.1016/j.molcel.2007.02.003.CrossRefPubMedPubMedCentral

Schachter, M. M., Merrick, K. A., Larochelle, S., Hirschi, A., Zhang, C., Shokat, K. M., Rubin, S. M., & Fisher, R. P. (2013). A Cdk7-Cdk4 T-loop phosphorylation Cascade promotes G1 progression. Molecular Cell, 50(2), 250–260. https://doi.org/10.1016/j.molcel.2013.04.003.CrossRefPubMedPubMedCentral

Bisteau, X., Paternot, S., Colleoni, B., Ecker, K., Coulonval, K., De Groote, P., et al. (2013). CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point. PLoS Genetics, 9(5), e1003546. https://doi.org/10.1371/journal.pgen.1003546.CrossRefPubMedPubMedCentral

Wong, K. H., Jin, Y., & Struhl, K. (2014). TFIIH phosphorylation of the pol II CTD stimulates mediator dissociation from the Preinitiation complex and promoter escape. Molecular Cell, 54(4), 601–612. https://doi.org/10.1016/j.molcel.2014.03.024.CrossRefPubMedPubMedCentral

Glover-Cutter, K., Larochelle, S., Erickson, B., Zhang, C., Shokat, K., Fisher, R. P., et al. (2009). TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Molecular and Cellular Biology, 29(20), 5455–5464. https://doi.org/10.1128/mcb.00637-09.CrossRefPubMedPubMedCentral

Akhtar, M. S., Heidemann, M., Tietjen, J. R., Zhang, D. W., Chapman, R. D., Eick, D., & Ansari, A. Z. (2009). TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. Molecular Cell, 34(3), 387–393. https://doi.org/10.1016/j.molcel.2009.04.016.CrossRefPubMedPubMedCentral

Larochelle, S., Amat, R., Glover-Cutter, K., Sansó, M., Zhang, C., Allen, J. J., et al. (2012). Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nature Structural & Molecular Biology, 19, 1108, https://doi.org/10.1038/nsmb.2399https://www.nature.com/articles/nsmb.2399#supplementary-information.

Ko, L. J., Shieh, S. Y., Chen, X., Jayaraman, L., Tamai, K., Taya, Y., Prives, C., & Pan, Z. Q. (1997). p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Molecular and Cellular Biology, 17(12), 7220–7229. https://doi.org/10.1128/mcb.17.12.7220.CrossRefPubMedPubMedCentral

10.

Lu, H., Fisher, R. P., Bailey, P., & Levine, A. J. (1997). The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Molecular and Cellular Biology, 17(10), 5923–5934. https://doi.org/10.1128/mcb.17.10.5923.CrossRefPubMedPubMedCentral

11.

Keriel, A., Stary, A., Sarasin, A., Rochette-Egly, C., & Egly, J.-M. (2002). XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RARα. Cell, 109(1), 125–135. https://doi.org/10.1016/S0092-8674(02)00692-X.CrossRefPubMed

12.

Bastien, J., Adam-Stitah, S., Riedl, T., Egly, J.-M., Chambon, P., & Rochette-Egly, C. (2000). TFIIH interacts with the retinoic acid receptor γ and phosphorylates its AF-1-activating domain through cdk7. Journal of Biological Chemistry, 275(29), 21896–21904. https://doi.org/10.1074/jbc.M001985200.CrossRefPubMed

13.

Rochette-Egly, C., Adam, S., Rossignol, M., Egly, J.-M., & Chambon, P. (1997). Stimulation of RARα activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell, 90(1), 97–107. https://doi.org/10.1016/S0092-8674(00)80317-7.CrossRefPubMed

14.

Chen, D., Riedl, T., Washbrook, E., Pace, P. E., Coombes, R. C., Egly, J.-M., & Ali, S. (2000). Activation of estrogen receptor α by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Molecular Cell, 6(1), 127–137. https://doi.org/10.1016/S1097-2765(05)00004-3.CrossRefPubMed

15.

Chen, D., Washbrook, E., Sarwar, N., Bates, G. J., Pace, P. E., Thirunuvakkarasu, V., Taylor, J., Epstein, R. J., Fuller-Pace, F. V., Egly, J. M., Coombes, R. C., & Ali, S. (2002). Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene, 21(32), 4921–4931. https://doi.org/10.1038/sj.onc.1205420.CrossRefPubMed

16.

Lee, D. K., Duan, H. O., & Chang, C. (2000). From Androgen receptor to the general transcription factor TFIIH: identification of cdk activating kinase (CAK) as an androgen receptor NH2- terminal associated coactivator. Journal of Biological Chemistry, 275(13), 9308–9313. https://doi.org/10.1074/jbc.275.13.9308.CrossRefPubMed

17.

Chymkowitch, P., Le May, N., Charneau, P., Compe, E., & Egly, J.-M. (2011). The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. The EMBO Journal, 30(3), 468–479. https://doi.org/10.1038/emboj.2010.337.CrossRefPubMed

18.

Galbraith, M. D., Bender, H., & Espinosa, J. M. (2019). Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription, 10(2), 118–136. https://doi.org/10.1080/21541264.2018.1539615.CrossRefPubMed

19.

Bradner, J. E., Hnisz, D., & Young, R. A. (2017). Transcriptional addiction in cancer. Cell, 168(4), 629–643. https://doi.org/10.1016/j.cell.2016.12.013.CrossRefPubMedPubMedCentral

20.

Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., Jenkins, C. E., Hannett, N. M., McMillin, D., Sanda, T., Sim, T., Kim, N. D., Look, T., Mitsiades, C. S., Weng, A. P., Brown, J. R., Benes, C. H., Marto, J. A., Young, R. A., & Gray, N. S. (2014). Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 511(7511), 616–620. https://doi.org/10.1038/nature13393.CrossRefPubMedPubMedCentral

21.

Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C., Altabef, A., Perez-Atayde, A., Wong, K. K., Yuan, G. C., Gray, N. S., Young, R. A., & George, R. E. (2014). CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell, 159(5), 1126–1139. https://doi.org/10.1016/j.cell.2014.10.024.CrossRefPubMedPubMedCentral

22.

Patel, H., Periyasamy, M., Sava, G. P., Bondke, A., Slafer, B. W., Kroll, S. H. B., Barbazanges, M., Starkey, R., Ottaviani, S., Harrod, A., Aboagye, E. O., Buluwela, L., Fuchter, M. J., Barrett, A. G. M., Coombes, R. C., & Ali, S. (2018). ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Molecular Cancer Therapeutics, 17(6), 1156–1166. https://doi.org/10.1158/1535-7163.Mct-16-0847.CrossRefPubMedPubMedCentral

23.

Hu, S., Marineau, J. J., Rajagopal, N., Hamman, K. B., Choi, Y. J., Schmidt, D. R., et al. (2019). Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Research, canres.0119.2019, https://doi.org/10.1158/0008-5472.Can-19-0119.

24.

Hu, S., Marineau, J., Hamman, K., Bradley, M., Savinainen, A., Alnemy, S., et al. (2019). Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo. Cancer Research, 79(13 Supplement), 4421–4421. https://doi.org/10.1158/1538-7445.Am2019-4421.CrossRef

25.

Johannessen, L. H., Hu, S., Ke, N., D'Ippolito, A., Rajagopal, N., Marineau, J., et al. (2019). Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications. Molecular Cancer Therapeutics, 18(12 Supplement), C091–C091. https://doi.org/10.1158/1535-7163.Targ-19-c091.CrossRef

26.

Coates, D. A., Montero, C., Patel, B. K. R., Remick, D. M., & Yadav, V. (2019). Compounds useful for inhibiting CDK7. United States: Eli Lilly and Company. IN, US: Indianapolis.

27.

Rimel, J. K., & Taatjes, D. J. (2018). The essential and multifunctional TFIIH complex. Protein Science, 27(6), 1018–1037. https://doi.org/10.1002/pro.3424.CrossRefPubMedPubMedCentral

28.

Lolli, G., Lowe, E. D., Brown, N. R., & Johnson, L. N. (2004). The crystal structure of human CDK7 and its protein recognition properties. Structure, 12(11), 2067–2079. https://doi.org/10.1016/j.str.2004.08.013.CrossRefPubMed

29.

Larochelle, S., Chen, J., Knights, R., Pandur, J., Morcillo, P., Erdjument-Bromage, H., Tempst, P., Suter, B., & Fisher, R. P. (2001). T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. The EMBO Journal, 20(14), 3749–3759. https://doi.org/10.1093/emboj/20.14.3749.CrossRefPubMedPubMedCentral

30.

Garrett, S., Barton, W. A., Knights, R., Jin, P., Morgan, D. O., & Fisher, R. P. (2001). Reciprocal activation by Cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Molecular and Cellular Biology, 21(1), 88–99. https://doi.org/10.1128/mcb.21.1.88-99.2001.CrossRefPubMedPubMedCentral

31.

Desai, S. R., Pillai, P. P., Patel, R. S., McCray, A. N., Win-Piazza, H. Y., & Acevedo-Duncan, M. E. (2011). Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase/PKC-ι-mediated signaling cascade in glioblastoma. Carcinogenesis, 33(1), 10–19. https://doi.org/10.1093/carcin/bgr231.CrossRefPubMedPubMedCentral

32.

Pillai, P., Desai, S., Patel, R., Sajan, M., Farese, R., Ostrov, D., & Acevedo-Duncan, M. (2011). A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma. The International Journal of Biochemistry & Cell Biology, 43(5), 784–794. https://doi.org/10.1016/j.biocel.2011.02.002.CrossRef

33.

Acevedo-Duncan, M., Patel, R., Whelan, S., & Bicaku, E. (2002). Human glioma PKC-ι and PKC-βII phosphorylate cyclin-dependent kinase activating kinase during the cell cycle. Cell Proliferation, 35(1), 23–36. https://doi.org/10.1046/j.1365-2184.2002.00220.x.CrossRefPubMedPubMedCentral

34.

Ni, S., Chen, L., Li, M., Zhao, W., Shan, X., Wu, M., Cheng, J., Liang, L., Wang, Y., Jiang, W., Zhang, J., & Ni, R. (2016). PKC iota promotes cellular proliferation by accelerated G1/S transition via interaction with CDK7 in esophageal squamous cell carcinoma. Tumor Biology, 37(10), 13799–13809. https://doi.org/10.1007/s13277-016-5193-9.CrossRefPubMed

35.

Ghezzi, C., Wong, A., Chen, B. Y., Ribalet, B., Damoiseaux, R., & Clark, P. M. (2019). A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells. Nature Communications, 10(1), 5444. https://doi.org/10.1038/s41467-019-13334-8.CrossRefPubMedPubMedCentral

36.

Schneider, E., Kartarius, S., Schuster, N., & Montenarh, M. (2002). The cyclin H/cdk7/Mat1 kinase activity is regulated by CK2 phosphorylation of cyclin H. Oncogene, 21(33), 5031–5037. https://doi.org/10.1038/sj.onc.1205690.CrossRefPubMed

37.

Akoulitchev, S., Chuikov, S., & Reinberg, D. (2000). TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature, 407(6800), 102–106. https://doi.org/10.1038/35024111.CrossRefPubMed

38.

Abdullah, A. I., Zhang, H., Nie, Y., Tang, W., & Sun, T. (2016). CDK7 and miR-210 co-regulate cell-cycle progression of neural progenitors in the developing Neocortex. Stem Cell Reports, 7(1), 69–79. https://doi.org/10.1016/j.stemcr.2016.06.005.CrossRefPubMedPubMedCentral

39.

Ali, S., Heathcote, D. A., Kroll, S. H. B., Jogalekar, A. S., Scheiper, B., Patel, H., Brackow, J., Siwicka, A., Fuchter, M. J., Periyasamy, M., Tolhurst, R. S., Kanneganti, S. K., Snyder, J. P., Liotta, D. C., Aboagye, E. O., Barrett, A. G. M., & Coombes, R. C. (2009). The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Research, 69(15), 6208–6215. https://doi.org/10.1158/0008-5472.Can-09-0301.CrossRefPubMedPubMedCentral

40.

Merrick, K. A., Larochelle, S., Zhang, C., Allen, J. J., Shokat, K. M., & Fisher, R. P. (2008). Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Molecular Cell, 32(5), 662–672. https://doi.org/10.1016/j.molcel.2008.10.022.CrossRefPubMedPubMedCentral

41.

Abdulrahman, W., Iltis, I., Radu, L., Braun, C., Maglott-Roth, A., Giraudon, C., Egly, J. M., & Poterszman, A. (2013). ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and transcription activities. Proceedings of the National Academy of Sciences, 110(8), E633–E642. https://doi.org/10.1073/pnas.1213981110.CrossRef

42.

Luo, J., Cimermancic, P., Viswanath, S., Ebmeier, C. C., Kim, B., Dehecq, M., Raman, V., Greenberg, C. H., Pellarin, R., Sali, A., Taatjes, D. J., Hahn, S., & Ranish, J. (2015). Architecture of the human and yeast general transcription and DNA repair factor TFIIH. Molecular Cell, 59(5), 794–806. https://doi.org/10.1016/j.molcel.2015.07.016.CrossRefPubMedPubMedCentral

43.

Tirode, F., Busso, D., Coin, F., & Egly, J.-M. (1999). Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7. Molecular Cell, 3(1), 87–95. https://doi.org/10.1016/S1097-2765(00)80177-X.CrossRefPubMed

44.

Bataille, A. R., Jeronimo, C., Jacques, P.-É., Laramée, L., Fortin, M.-È., Forest, A., Bergeron, M., Hanes, S. D., & Robert, F. (2012). A universal RNA polymerase II CTD cycle is orchestrated by complex interplays between kinase, phosphatase, and isomerase enzymes along genes. Molecular Cell, 45(2), 158–170. https://doi.org/10.1016/j.molcel.2011.11.024.CrossRefPubMed

45.

Jeronimo, C., & Robert, F. (2014). Kin28 regulates the transient association of mediator with core promoters. Nature Structural & Molecular Biology, 21(5), 449–455. https://doi.org/10.1038/nsmb.2810.CrossRef

46.

Egloff, S., O'Reilly, D., Chapman, R. D., Taylor, A., Tanzhaus, K., Pitts, L., Eick, D., & Murphy, S. (2007). Serine-7 of the RNA polymerase II CTD is specifically required for snRNA gene expression. Science, 318(5857), 1777–1779. https://doi.org/10.1126/science.1145989.CrossRefPubMedPubMedCentral

47.

Glover-Cutter, K., Kim, S., Espinosa, J., & Bentley, D. L. (2007). RNA polymerase II pauses and associates with pre-mRNA processing factors at both ends of genes. Nature Structural & Molecular Biology, 15, 71. https://doi.org/10.1038/nsmb1352https://www.nature.com/articles/nsmb1352#supplementary-information.

48.

Kwak, H., & Lis, J. T. (2013). Control of transcriptional elongation. Annual Review of Genetics, 47, 483–508. https://doi.org/10.1146/annurev-genet-110711-155440.CrossRefPubMedPubMedCentral

49.

Yamaguchi, Y., Takagi, T., Wada, T., Yano, K., Furuya, A., Sugimoto, S., Hasegawa, J., & Handa, H. (1999). NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell, 97(1), 41–51. https://doi.org/10.1016/S0092-8674(00)80713-8.CrossRefPubMed

50.

Nilson, K. A., Guo, J., Turek, M. E., Brogie, J. E., Delaney, E., Luse, D. S., & Price, D. H. (2015). THZ1 reveals roles for Cdk7 in co-transcriptional capping and pausing. Molecular Cell, 59(4), 576–587. https://doi.org/10.1016/j.molcel.2015.06.032.CrossRefPubMedPubMedCentral

51.

Ebmeier, C. C., Erickson, B., Allen, B. L., Allen, M. A., Kim, H., Fong, N., Jacobsen, J. R., Liang, K., Shilatifard, A., Dowell, R. D., Old, W. M., Bentley, D. L., & Taatjes, D. J. (2017). Human TFIIH kinase CDK7 regulates transcription-associated chromatin modifications. Cell Reports, 20(5), 1173–1186. https://doi.org/10.1016/j.celrep.2017.07.021.CrossRefPubMed

52.

Bacon, C. W., & D’Orso, I. (2019). CDK9: A signaling hub for transcriptional control. Transcription, 10(2), 57–75. https://doi.org/10.1080/21541264.2018.1523668.CrossRefPubMed

53.

Bartkowiak, B., Liu, P., Phatnani, H. P., Fuda, N. J., Cooper, J. J., Price, D. H., Adelman, K., Lis, J. T., & Greenleaf, A. L. (2010). CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes & Development, 24(20), 2303–2316. https://doi.org/10.1101/gad.1968210.CrossRef

54.

Bösken, C. A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., et al. (2014). The structure and substrate specificity of human Cdk12/Cyclin K. Nature Communications, 5, 3505, https://doi.org/10.1038/ncomms4505https://www.nature.com/articles/ncomms4505#supplementary-information.

55.

Liang, K., Gao, X., Gilmore, J. M., Florens, L., Washburn, M. P., Smith, E., & Shilatifard, A. (2015). Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Molecular and Cellular Biology, 35(6), 928–938. https://doi.org/10.1128/mcb.01426-14.CrossRefPubMedPubMedCentral

56.

Greifenberg, A. K., Hönig, D., Pilarova, K., Düster, R., Bartholomeeusen, K., Bösken, C. A., Anand, K., Blazek, D., & Geyer, M. (2016). Structural and functional analysis of the Cdk13/Cyclin K complex. Cell Reports, 14(2), 320–331. https://doi.org/10.1016/j.celrep.2015.12.025.CrossRefPubMed

57.

Rossi, D. J., Londesborough, A., Korsisaari, N., Pihlak, A., Lehtonen, E., Henkemeyer, M., & Mäkelä, T. P. (2001). Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking Mat1. The EMBO Journal, 20(11), 2844–2856. https://doi.org/10.1093/emboj/20.11.2844.CrossRefPubMedPubMedCentral

58.

Ganuza, M., Sáiz-Ladera, C., Cañamero, M., Gómez, G., Schneider, R., Blasco, M. A., Pisano, D., Paramio, J. M., Santamaría, D., & Barbacid, M. (2012). Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. The EMBO Journal, 31(11), 2498–2510. https://doi.org/10.1038/emboj.2012.94.CrossRefPubMedPubMedCentral

59.

Ali, S., Metzger, D., Bornert, J. M., & Chambon, P. (1993). Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. The EMBO Journal, 12(3), 1153–1160. https://doi.org/10.1002/j.1460-2075.1993.tb05756.x.CrossRefPubMedPubMedCentral

60.

Valley, C. C., Métivier, R., Solodin, N. M., Fowler, A. M., Mashek, M. T., Hill, L., et al. (2005). Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor α N terminus. Molecular and Cellular Biology, 25(13), 5417–5428. https://doi.org/10.1128/mcb.25.13.5417-5428.2005.CrossRefPubMedPubMedCentral

61.

Drané, P., Compe, E., Catez, P., Chymkowitch, P., & Egly, J.-M. (2004). Selective regulation of vitamin D receptor-responsive genes by TFIIH. Molecular Cell, 16(2), 187–197. https://doi.org/10.1016/j.molcel.2004.10.007.CrossRefPubMed

62.

Compe, E., Drané, P., Laurent, C., Diderich, K., Braun, C., Hoeijmakers, J. H. J., et al. (2005). Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations. Molecular and Cellular Biology, 25(14), 6065–6076. https://doi.org/10.1128/mcb.25.14.6065-6076.2005.CrossRefPubMedPubMedCentral

63.

Vandel, L., & Kouzarides, T. (1999). Residues phosphorylated by TFIIH are required for E2F-1 degradation during S-phase. The EMBO Journal, 18(15), 4280–4291. https://doi.org/10.1093/emboj/18.15.4280.CrossRefPubMedPubMedCentral

64.

Cho, Y. S., Li, S., Wang, X., Zhu, J., Zhuo, S., Han, Y., Yue, T., Yang, Y., & Jiang, J. (2019). CDK7 regulates organ size and tumor growth by safeguarding the hippo pathway effector Yki/yap/Taz in the nucleus. Genes & Development, 34, 53–71. https://doi.org/10.1101/gad.333146.119.CrossRef

65.

Coin, F., Oksenych, V., Mocquet, V., Groh, S., Blattner, C., & Egly, J. M. (2008). Nucleotide excision repair driven by the dissociation of CAK from TFIIH. Molecular Cell, 31(1), 9–20. https://doi.org/10.1016/j.molcel.2008.04.024.CrossRefPubMed

66.

Araújo, S. J., Tirode, F., Coin, F., Pospiech, H., Syväoja, J. E., Stucki, M., Hübscher, U., Egly, J. M., & Wood, R. D. (2000). Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes & Development, 14(3), 349–359. https://doi.org/10.1101/gad.14.3.349.CrossRef

67.

Bartkova, J., Zemanova, M., & Bartek, J. (1996). Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell-cycle position and differentiation. International Journal of Cancer, 66(6), 732–737. https://doi.org/10.1002/(sici)1097-0215(19960611)66:6<732::Aid-ijc4>3.0.Co;2-0.CrossRefPubMed

68.

Patel, H., Abduljabbar, R., Lai, C.-F., Periyasamy, M., Harrod, A., Gemma, C., Steel, J. H., Patel, N., Busonero, C., Jerjees, D., Remenyi, J., Smith, S., Gomm, J. J., Magnani, L., Gyorffy, B., Jones, L. J., Fuller-Pace, F., Shousha, S., Buluwela, L., Rakha, E. A., Ellis, I. O., Coombes, R. C., & Ali, S. (2016). Expression of CDK7, cyclin H, and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor–positive breast cancer. Clinical Cancer Research, 22(23), 5929–5938. https://doi.org/10.1158/1078-0432.Ccr-15-1104.CrossRefPubMedPubMedCentral

69.

Wang, Q., Li, M., Zhang, X., Huang, H., Huang, J., Ke, J., Ding, H., Xiao, J., Shan, X., Liu, Q., Bao, B., & Yang, L. (2016). Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis. Experimental and Molecular Pathology, 100(3), 514–521. https://doi.org/10.1016/j.yexmp.2016.05.001.CrossRefPubMed

70.

Naseh, G., Mohammadifard, M., & Mohammadifard, M. (2016). Upregulation of cyclin-dependent kinase 7 and matrix metalloproteinase-14 expression contribute to metastatic properties of gastric cancer. IUBMB Life, 68(10), 799–805. https://doi.org/10.1002/iub.1543.CrossRefPubMed

71.

Jiang, L., Huang, R., Wu, Y., Diao, P., Zhang, W., Li, J., Li, Z., Wang, Y., Cheng, J., & Yang, J. (2019). Overexpression of CDK7 is associated with unfavourable prognosis in oral squamous cell carcinoma. Pathology, 51(1), 74–80. https://doi.org/10.1016/j.pathol.2018.10.004.CrossRefPubMed

72.

Tsang, F. H.-C., Law, C.-T., Tang, T.-C. C., Cheng, C. L.-H., Chin, D. W.-C., Tam, W.-S. V., Wei, L., Wong, C. C. L., Ng, I. O. L., & Wong, C. M. (2019). Aberrant super-enhancer landscape in human hepatocellular carcinoma. Hepatology, 69(6), 2502–2517. https://doi.org/10.1002/hep.30544.CrossRefPubMed

73.

Meng, W., Wang, J., Wang, B., Liu, F., Li, M., Zhao, Y., Zhang, C., Li, Q., Chen, J., Zhang, L., Tang, Y., & Ma, J. (2018). CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo. Cancer Management and Research, 10, 5747–5758. https://doi.org/10.2147/CMAR.S183696.CrossRefPubMedPubMedCentral

74.

Li, B., Ni Chonghaile, T., Fan, Y., Madden, S. F., Klinger, R., O'Connor, A. E., Walsh, L., O'Hurley, G., Mallya Udupi, G., Joseph, J., Tarrant, F., Conroy, E., Gaber, A., Chin, S. F., Bardwell, H. A., Provenzano, E., Crown, J., Dubois, T., Linn, S., Jirstrom, K., Caldas, C., O'Connor, D. P., & Gallagher, W. M. (2017). Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer. Cancer Research, 77(14), 3834–3845. https://doi.org/10.1158/0008-5472.Can-16-2546.CrossRefPubMed

75.

Zhang, Z., Peng, H., Wang, X., Yin, X., Ma, P., Jing, Y., Cai, M. C., Liu, J., Zhang, M., Zhang, S., Shi, K., Gao, W. Q., di, W., & Zhuang, G. (2017). Preclinical efficacy and molecular mechanism of targeting CDK7-dependent transcriptional addiction in ovarian cancer. Molecular Cancer Therapeutics, 16(9), 1739–1750. https://doi.org/10.1158/1535-7163.Mct-17-0078.CrossRefPubMed

76.

Pavey, S., Johansson, P., Packer, L., Taylor, J., Stark, M., Pollock, P. M., Walker, G. J., Boyle, G. M., Harper, U., Cozzi, S. J., Hansen, K., Yudt, L., Schmidt, C., Hersey, P., Ellem, K. A. O., O'Rourke, M. G. E., Parsons, P. G., Meltzer, P., Ringnér, M., & Hayward, N. K. (2004). Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene, 23(23), 4060–4067. https://doi.org/10.1038/sj.onc.1207563.CrossRefPubMed

77.

Johansson, P., Pavey, S., & Hayward, N. (2007). Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Research, 20(3), 216–221. https://doi.org/10.1111/j.1600-0749.2007.00375.x.CrossRefPubMed

78.

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., Leiserson, M. D. M., Miller, C. A., Welch, J. S., Walter, M. J., Wendl, M. C., Ley, T. J., Wilson, R. K., Raphael, B. J., & Ding, L. (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502(7471), 333–339. https://doi.org/10.1038/nature12634.CrossRefPubMedPubMedCentral

79.

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014). Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505(7484), 495–501. https://doi.org/10.1038/nature12912.CrossRefPubMedPubMedCentral

80.

Lane, D., & Levine, A. (2010). p53 research: the past thirty years and the next thirty years. Cold Spring Harbor Perspectives in Biology, 2(12). https://doi.org/10.1101/cshperspect.a000893.

81.

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., Mc Henry, K. T., Pinchback, R. M., Ligon, A. H., Cho, Y. J., Haery, L., Greulich, H., Reich, M., Winckler, W., Lawrence, M. S., Weir, B. A., Tanaka, K. E., Chiang, D. Y., Bass, A. J., Loo, A., Hoffman, C., Prensner, J., Liefeld, T., Gao, Q., Yecies, D., Signoretti, S., Maher, E., Kaye, F. J., Sasaki, H., Tepper, J. E., Fletcher, J. A., Tabernero, J., Baselga, J., Tsao, M. S., Demichelis, F., Rubin, M. A., Janne, P. A., Daly, M. J., Nucera, C., Levine, R. L., Ebert, B. L., Gabriel, S., Rustgi, A. K., Antonescu, C. R., Ladanyi, M., Letai, A., Garraway, L. A., Loda, M., Beer, D. G., True, L. D., Okamoto, A., Pomeroy, S. L., Singer, S., Golub, T. R., Lander, E. S., Getz, G., Sellers, W. R., & Meyerson, M. (2010). The landscape of somatic copy-number alteration across human cancers. Nature, 463(7283), 899–905. https://doi.org/10.1038/nature08822.CrossRefPubMedPubMedCentral

82.

Clemons, M., Danson, S., & Howell, A. (2002). Tamoxifen (‘Nolvadex’): a review: Antitumour treatment. Cancer Treatment Reviews, 28(4), 165–180. https://doi.org/10.1016/S0305-7372(02)00036-1.CrossRefPubMed

83.

Nathan, M. R., & Schmid, P. (2017). A review of fulvestrant in breast cancer. Oncology and Therapy, 5(1), 17–29. https://doi.org/10.1007/s40487-017-0046-2.CrossRefPubMed

84.

Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013). Super-enhancers in the control of cell identity and disease. Cell, 155(4), 934–947. https://doi.org/10.1016/j.cell.2013.09.053.CrossRefPubMed

85.

Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017). Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacology & Therapeutics, 173, 83–105. https://doi.org/10.1016/j.pharmthera.2017.02.008.CrossRef

86.

Conroy, A., Stockett, D. E., Walker, D., Arkin, M. R., Hoch, U., Fox, J. A., & Hawtin, R. E. (2009). SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemotherapy and Pharmacology, 64(4), 723–732. https://doi.org/10.1007/s00280-008-0921-5.CrossRefPubMed

87.

Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., & Sausville, E. (1992). Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. JNCI: Journal of the National Cancer Institute, 84(22), 1736–1740. https://doi.org/10.1093/jnci/84.22.1736.CrossRefPubMed

88.

Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., & Worland, P. J. (1994). Potent inhibition of Cdc2 kinase activity by the flavonoid L86-8275. Biochemical and Biophysical Research Communications, 201(2), 589–595. https://doi.org/10.1006/bbrc.1994.1742.CrossRefPubMed

89.

Carlson, B. A., Dubay, M. M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996). Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Research, 56(13), 2973–2978.PubMed

90.

Chen, R., Keating, M. J., Gandhi, V., & Plunkett, W. (2005). Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood, 106(7), 2513–2519. https://doi.org/10.1182/blood-2005-04-1678.CrossRefPubMedPubMedCentral

91.

Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015). The history and future of targeting cyclin-dependent kinases in cancer therapy. [review article]. Nature Reviews Drug Discovery, 14, 130. https://doi.org/10.1038/nrd4504https://www.nature.com/articles/nrd4504#supplementary-information.

92.

Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L. J., Johnson, A. J., Lucas, D. M., Heerema, N. A., Lozanski, G., Young, D. C., Suarez, J. R., Colevas, A. D., & Grever, M. R. (2006). Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 109(2), 399–404. https://doi.org/10.1182/blood-2006-05-020735.CrossRefPubMed

93.

Byrd, J. C., Peterson, B. L., Gabrilove, J., Odenike, O. M., Grever, M. R., Rai, K., Larson, R. A., & Cancer and Leukemia Group B. (2005). Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from cancer and leukemia group B study 19805. Clinical Cancer Research, 11(11), 4176–4181. https://doi.org/10.1158/1078-0432.Ccr-04-2276.CrossRefPubMed

94.

Kouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D., Meyer, R., Lohmann, R., Lopez, P., Powers, J., Turner, R., Connors, J. M., & National Cancer Institute of Canada Clinical Trials Group. (2003). Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 21(9), 1740–1745. https://doi.org/10.1200/jco.2003.09.057.CrossRefPubMed

95.

Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J. G., & Moulinoux, J. P. (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European Journal of Biochemistry, 243(1–2), 527–536. https://doi.org/10.1111/j.1432-1033.1997.t01-2-00527.x.CrossRefPubMed

96.

Whittaker, S. R., Walton, M. I., Garrett, M. D., & Workman, P. (2004). The cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Research, 64(1), 262–272. https://doi.org/10.1158/0008-5472.Can-03-0110.CrossRefPubMed

97.

McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., Zhelev, N., Zheleva, D., & Lane, D. P. (2002). In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). International Journal of Cancer, 102(5), 463–468. https://doi.org/10.1002/ijc.10738.CrossRefPubMed

98.

Benson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., Cassidy, J., Gianella-Borradori, A., Judson, I., & Twelves, C. (2007). A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. British Journal of Cancer, 96(1), 29–37. https://doi.org/10.1038/sj.bjc.6603509.CrossRefPubMed

99.

Misra, R. N., Xiao, H.-y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., et al. (2004). N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. Journal of Medicinal Chemistry, 47(7), 1719–1728. https://doi.org/10.1021/jm0305568.CrossRefPubMed

100.

Nuwayhid, S., Stockett, D., Hyde, J., Aleshin, A., Walker, D. H., & Arkin, M. R. SNS-032 is a potent and selective inhibitor of Cdk2, 7 and 9 and induces cell death by inhibiting cell cycle progression and the expression of antiapoptotic proteins. In Proc Am Assoc Cancer Res, 2006 (Vol. 47, pp. 491).

101.

Tong, W.-G., Chen, R., Plunkett, W., Siegel, D., Sinha, R., Harvey, R. D., Badros, A. Z., Popplewell, L., Coutre, S., Fox, J. A., Mahadocon, K., Chen, T., Kegley, P., Hoch, U., & Wierda, W. G. (2010). Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. Journal of Clinical Oncology, 28(18), 3015–3022. https://doi.org/10.1200/jco.2009.26.1347.CrossRefPubMedPubMedCentral

102.

Heath, E. I., Bible, K., Martell, R. E., Adelman, D. C., & LoRusso, P. M. (2008). A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Investigational New Drugs, 26(1), 59–65. https://doi.org/10.1007/s10637-007-9090-3.CrossRefPubMed

103.

Aklilu, M., Kindler, H. L., Donehower, R. C., Mani, S., & Vokes, E. E. (2003). Phase II study of flavopiridol in patients with advanced colorectal cancer. Annals of Oncology, 14(8), 1270–1273. https://doi.org/10.1093/annonc/mdg343.CrossRefPubMed

104.

Burdette-Radoux, S., Tozer, R. G., Lohmann, R. C., Quirt, I., Ernst, D. S., Walsh, W., Wainman, N., Colevas, A. D., & Eisenhauer, E. A. (2004). Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Investigational New Drugs, 22(3), 315–322. https://doi.org/10.1023/B:DRUG.0000026258.02846.1c.CrossRefPubMed

105.

Le Tourneau, C., Faivre, S., Laurence, V., Delbaldo, C., Vera, K., Girre, V., et al. (2010). Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. European Journal of Cancer, 46(18), 3243–3250. https://doi.org/10.1016/j.ejca.2010.08.001.CrossRefPubMed

106.

Marra, A., & Curigliano, G. (2019). Are all cyclin-dependent kinases 4/6 inhibitors created equal? npj Breast Cancer, 5(1), 27. https://doi.org/10.1038/s41523-019-0121-y.CrossRefPubMedPubMedCentral

107.

Hazel, P., Kroll, S. H. B., Bondke, A., Barbazanges, M., Patel, H., Fuchter, M. J., Coombes, R. C., Ali, S., Barrett, A. G. M., & Freemont, P. S. (2017). Inhibitor selectivity for cyclin-dependent kinase 7: a structural, thermodynamic, and Modelling study. ChemMedChem, 12(5), 372–380. https://doi.org/10.1002/cmdc.201600535.CrossRefPubMed

108.

Kelso, T. W., Baumgart, K., Eickhoff, J., Albert, T., Antrecht, C., Lemcke, S., et al. (2014). Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Molecular and Cellular Biology, 34(19), 3675–3688. https://doi.org/10.1128/mcb.00595-14.CrossRefPubMedPubMedCentral

109.

Choi, Y. J., Kim, D. H., Yoon, D. H., Suh, C., Choi, C.-M., Lee, J. C., Hong, J. Y., & Rho, J. K. (2019). Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma. Scientific Reports, 9(1), 7193. https://doi.org/10.1038/s41598-019-43760-z.CrossRefPubMedPubMedCentral

110.

Wang, B. Y., Liu, Q. Y., Cao, J., Chen, J. W., & Liu, Z. S. (2016). Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer. Drug Design, Development and Therapy, 10, 1181–1189. https://doi.org/10.2147/dddt.S86317.CrossRefPubMedPubMedCentral

111.

Gong, Y., Yang, J., Liu, F., Li, Z., Gong, R., & Wei, T. (2018). Cyclin-dependent kinase 7 is a potential therapeutic target in papillary thyroid carcinoma. Journal of Biological Regulators and Homeostatic Agents, 32(6), 1361–1368.PubMed

112.

Clark, K., Ainscow, E., Peall, A., Thomson, S., Leishman, A., Elaine, S., et al. (2017). CT7001, a novel orally bio-available CDK7 inhibitor, is highly active in in-vitro and in-vivo models of AML. Blood, 130(Suppl 1), 2645–2645.

113.

Hutterer, C., Eickhoff, J., Milbradt, J., Korn, K., Zeittrager, I., Bahsi, H., et al. (2015). A novel CDK7 inhibitor of the pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrobial Agents and Chemotherapy, 59(4), 2062–2071. https://doi.org/10.1128/aac.04534-14.CrossRefPubMedPubMedCentral

114.

Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., et al. (2014). Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell, 26(6), 909–922. https://doi.org/10.1016/j.ccell.2014.10.019.CrossRefPubMedPubMedCentral

115.

Cayrol, F., Praditsuktavorn, P., Fernando, T. M., Kwiatkowski, N., Marullo, R., Calvo-Vidal, M. N., Phillip, J., Pera, B., Yang, S. N., Takpradit, K., Roman, L., Gaudiano, M., Crescenzo, R., Ruan, J., Inghirami, G., Zhang, T., Cremaschi, G., Gray, N. S., & Cerchietti, L. (2017). THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nature Communications, 8(1), 14290. https://doi.org/10.1038/ncomms14290.CrossRefPubMedPubMedCentral

116.

Nagaraja, S., Vitanza, N. A., Woo, P. J., Taylor, K. R., Liu, F., Zhang, L., et al. (2017). Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell, 31(5), 635–652.e636. https://doi.org/10.1016/j.ccell.2017.03.011.CrossRefPubMedPubMedCentral

117.

Greenall, S. A., Lim, Y. C., Mitchell, C. B., Ensbey, K. S., Stringer, B. W., Wilding, A. L., O'Neill, G. M., McDonald, K. L., Gough, D. J., Day, B. W., & Johns, T. G. (2017). Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma. Oncogenesis, 6(5), e336. https://doi.org/10.1038/oncsis.2017.33.CrossRefPubMedPubMedCentral

118.

Eliades, P., Abraham, B. J., Ji, Z., Miller, D. M., Christensen, C. L., Kwiatkowski, N., Kumar, R., Njauw, C. N., Taylor, M., Miao, B., Zhang, T., Wong, K. K., Gray, N. S., Young, R. A., & Tsao, H. (2018). High MITF expression is associated with super-enhancers and suppressed by CDK7 inhibition in melanoma. Journal of Investigative Dermatology, 138(7), 1582–1590. https://doi.org/10.1016/j.jid.2017.09.056.CrossRefPubMed

119.

Zhong, L., Yang, S., Jia, Y., & Lei, K. (2018). Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis. Journal of Cellular Biochemistry, 119(12), 9742–9751. https://doi.org/10.1002/jcb.27292.CrossRefPubMed

120.

Cao, X., Dang, L., Zheng, X., Lu, Y., Lu, Y., Ji, R., Zhang, T., Ruan, X., Zhi, J., Hou, X., Yi, X., Li, M. J., Gu, T., Gao, M., Zhang, L., & Chen, Y. (2019). Targeting super-enhancer-driven oncogenic transcription by CDK7 inhibition in anaplastic thyroid carcinoma. Thyroid, 29(6), 809–823. https://doi.org/10.1089/thy.2018.0550.CrossRefPubMed

121.

Lu, P., Geng, J., Zhang, L., Wang, Y., Niu, N., Fang, Y., Liu, F., Shi, J., Zhang, Z. G., Sun, Y. W., Wang, L. W., Tang, Y., & Xue, J. (2019). THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Oncogene, 38(20), 3932–3945. https://doi.org/10.1038/s41388-019-0701-1.CrossRefPubMed

122.

Zhong, S., Zhang, Y., Yin, X., & Di, W. (2019). CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer. OncoTargets and Theraphy, 12, 2137–2147. https://doi.org/10.2147/ott.S195655.CrossRef

123.

Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., von, T., Li, H., Lin, Z., Stover, D. G., Lim, E., Wang, Z. C., Iglehart, J. D., Young, R. A., Gray, N. S., & Zhao, J. J. (2015). CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell, 163(1), 174–186. https://doi.org/10.1016/j.cell.2015.08.063.CrossRefPubMedPubMedCentral

124.

Zhang, Y., Zhou, L., Bandyopadhyay, D., Sharma, K., Allen, A. J., Kmieciak, M., & Grant, S. (2019). The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in vitro and in vivo. Clinical Cancer Research, 25, 6195–6205. https://doi.org/10.1158/1078-0432.Ccr-18-3788.CrossRefPubMedPubMedCentral

125.

Harrod, A., Fulton, J., Nguyen, V. T. M., Periyasamy, M., Ramos-Garcia, L., Lai, C. F., et al. (2016). Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene, 36, 2286, https://doi.org/10.1038/onc.2016.382https://www.nature.com/articles/onc2016382#supplementary-information.

126.

Durbin, A. D., Zimmerman, M. W., Dharia, N. V., Abraham, B. J., Iniguez, A. B., Weichert-Leahey, N., He, S., Krill-Burger, J. M., Root, D. E., Vazquez, F., Tsherniak, A., Hahn, W. C., Golub, T. R., Young, R. A., Look, A. T., & Stegmaier, K. (2018). Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature Genetics, 50(9), 1240–1246. https://doi.org/10.1038/s41588-018-0191-z.CrossRefPubMedPubMedCentral

127.

Huang, T., Ding, X., Xu, G., Chen, G., Cao, Y., Peng, C., Shen, S., Lv, Y., Wang, L., & Zou, X. (2019). CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263. Cell Death & Disease, 10(8), 602. https://doi.org/10.1038/s41419-019-1831-7.CrossRef

128.

Kalan, S., Amat, R., Schachter, M. M., Kwiatkowski, N., Abraham, B. J., Liang, Y., Zhang, T., Olson, C. M., Larochelle, S., Young, R. A., Gray, N. S., & Fisher, R. P. (2017). Activation of the p53 transcriptional program sensitizes cancer cells to Cdk7 inhibitors. Cell Reports, 21(2), 467–481. https://doi.org/10.1016/j.celrep.2017.09.056.CrossRefPubMed

129.

Huang, J.-R., Qin, W.-M., Wang, K., Fu, D.-R., Zhang, W.-J., Jiang, Q.-W., Yang, Y., Yuan, M. L., Xing, Z. H., Wei, M. N., Li, Y., & Shi, Z. (2018). Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo. American Journal of Translational Research, 10(11), 3664–3676.PubMedPubMedCentral

130.

Olson, C. M., Liang, Y., Leggett, A., Park, W. D., Li, L., Mills, C. E., Elsarrag, S. Z., Ficarro, S. B., Zhang, T., Düster, R., Geyer, M., Sim, T., Marto, J. A., Sorger, P. K., Westover, K. D., Lin, C. Y., Kwiatkowski, N., & Gray, N. S. (2019). Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chemical Biology, 26, 792–803.e10. https://doi.org/10.1016/j.chembiol.2019.02.012.CrossRefPubMedPubMedCentral

131.

Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., et al. (2020). CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell, 37(1), 37–54.e39. https://doi.org/10.1016/j.ccell.2019.11.003.CrossRefPubMed

132.

Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., et al. (2016). Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nature Chemical Biology, 12, 876. https://doi.org/10.1038/nchembio.2166https://www.nature.com/articles/nchembio.2166#supplementary-information.CrossRefPubMedPubMedCentral

133.

MacCallum, D. E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D. P., & Green, S. R. (2005). Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II–dependent transcription and down-regulation of Mcl-1. Cancer Research, 65(12), 5399–5407. https://doi.org/10.1158/0008-5472.Can-05-0233.CrossRefPubMed

134.

Shandilya, J., Wang, Y., & Roberts, S. G. E. (2012). TFIIB dephosphorylation links transcription inhibition with the p53-dependent DNA damage response. Proceedings of the National Academy of Sciences, 109(46), 18797–18802. https://doi.org/10.1073/pnas.1207483109.CrossRef

135.

Wong, R. W. J., Ngoc, P. C. T., Leong, W. Z., Yam, A. W. Y., Zhang, T., Asamitsu, K., Iida, S., Okamoto, T., Ueda, R., Gray, N. S., Ishida, T., & Sanda, T. (2017). Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. Blood, 130(21), 2326–2338. https://doi.org/10.1182/blood-2017-06-792184.CrossRefPubMedPubMedCentral

136.

Sharifnia, T., Wawer, M. J., Chen, T., Huang, Q.-Y., Weir, B. A., Sizemore, A., Lawlor, M. A., Goodale, A., Cowley, G. S., Vazquez, F., Ott, C. J., Francis, J. M., Sassi, S., Cogswell, P., Sheppard, H. E., Zhang, T., Gray, N. S., Clarke, P. A., Blagg, J., Workman, P., Sommer, J., Hornicek, F., Root, D. E., Hahn, W. C., Bradner, J. E., Wong, K. K., Clemons, P. A., Lin, C. Y., Kotz, J. D., & Schreiber, S. L. (2019). Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nature Medicine, 25(2), 292–300. https://doi.org/10.1038/s41591-018-0312-3.CrossRefPubMedPubMedCentral

137.

Rasool, R. U., Natesan, R., Deng, Q., Aras, S., Lal, P., Sander Effron, S., et al. (2019). CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation. Cancer Discovery, CD-19-0189. https://doi.org/10.1158/2159-8290.Cd-19-0189.

138.

Jeselsohn, R., Bergholz, J. S., Pun, M., Cornwell, M., Liu, W., Nardone, A., et al. (2018). Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell, 33(2), 173–186.e175. https://doi.org/10.1016/j.ccell.2018.01.004.CrossRefPubMedPubMedCentral

139.

Sun, B., Mason, S., Wilson, R. C., Hazard, S. E., Wang, Y., Fang, R., Wang, Q., Yeh, E. S., Yang, M., Roberts, T. M., Zhao, J. J., & Wang, Q. (2019). Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene, 39, 50–63. https://doi.org/10.1038/s41388-019-0953-9.CrossRefPubMedPubMedCentral

140.

Martin, L.-A., Pancholi, S., Ribas, R., Gao, Q., Simigdala, N., Nikitorowicz-Buniak, J., et al. (2017). Abstract P3-03-09: resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome. Cancer Research, 77(4 Supplement), P3-03-09-P03-03-09. https://doi.org/10.1158/1538-7445.Sabcs16-p3-03-09.CrossRef

141.

Alqahtani, A., Choucair, K., Ashraf, M., Hammouda, D. M., Alloghbi, A., Khan, T., Senzer, N., & Nemunaitis, J. (2019). Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Science OA, 5(3), FSO372. https://doi.org/10.4155/fsoa-2018-0115.CrossRefPubMedPubMedCentral

142.

Gao, Y., Zhang, T., Terai, H., Ficarro, S. B., Kwiatkowski, N., Hao, M.-F., et al. (2018). Overcoming resistance to the THZ series of covalent transcriptional CDK inhibitors. Cell Chemical Biology, 25(2), 135–142.e135. https://doi.org/10.1016/j.chembiol.2017.11.007.CrossRefPubMed

143.

Sava, G. P., Fan, H., Fisher, R. A., Lusvarghi, S., Pancholi, S., Ambudkar, S. V., Martin, L. A., Charles Coombes, R., Buluwela, L., & Ali, S. (2019). ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942. Oncogene, 39, 651–663. https://doi.org/10.1038/s41388-019-1008-y.CrossRefPubMedPubMedCentral

144.

Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018). Revisiting the role of ABC transporters in multidrug-resistant cancer. Nature Reviews Cancer, 18(7), 452–464. https://doi.org/10.1038/s41568-018-0005-8.CrossRefPubMedPubMedCentral

145.

Kaliszczak, M., Patel, H., Kroll, S. H. B., Carroll, L., Smith, G., Delaney, S., Heathcote, D. A., Bondke, A., Fuchter, M. J., Coombes, R. C., Barrett, A. G. M., Ali, S., & Aboagye, E. O. (2013). Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance. British Journal of Cancer, 109(9), 2356–2367. https://doi.org/10.1038/bjc.2013.584.CrossRefPubMedPubMedCentral

Title: CDK7 inhibitors as anticancer drugs
Authors: Georgina P. Sava
Hailing Fan
R. Charles Coombes
Lakjaya Buluwela
Simak Ali
Publication date: 01-09-2020
Publisher: Springer US
Keyword: Cancer Therapy
Published in: Cancer and Metastasis Reviews / Issue 3/2020
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-020-09885-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Role of linoleic acid-derived oxylipins in cancer

Multiple roles of HOX proteins in Metastasis: Let me count the ways

MDA-9/Syntenin/SDCBP: new insights into a unique multifunctional scaffold protein

The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment

Preface

KISS1 in metastatic cancer research and treatment: potential and paradoxes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer